PerspectiveMicrobiology

Exploiting Malaria Drug Resistance to Our Advantage

See allHide authors and affiliations

Science  05 Aug 2011:
Vol. 333, Issue 6043, pp. 705-706
DOI: 10.1126/science.1210875

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

In the world of developing anti-infective drugs, resistance comes with the territory. It is literally in the DNA (or RNA) of the viruses and pathogens targeted for treatment. Because resistance has far-reaching consequences for human health, researchers have studied the resistance of infectious agents such as human immunodeficiency virus (HIV) type 1 with unprecedented intensity and documented in excruciating detail the genetic determinants of resistance to FDA-approved drugs (1). However, understanding drug resistance in a complex eukaryotic parasite, such as the Plasmodium parasite that causes malaria, is a very different challenge. On page 724 of this issue, Yuan et al. (2) confront the issue head-on. Using high-throughput chemical and gene analysis methods, they not only identify potential new antimalarial drugs that could be used in combination to suppress the development of drug resistance but also characterize a common set of genetic loci and genes affected by these molecules.

View Full Text